One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection in non-HIV Population: a randomized controlled trial
Clinical Microbiology and Infection · 2024
DOI: 10.1016/j.cmi.2024.06.024 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Microbiology and Infection, 2024. Verfasst von Hung-Ling Huang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; Division of Pulmonar…. Hauptthemen laut MEDLINE: Isoniazid, Latent Tuberculosis, Rifampin, Antitubercular Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Kaohsiung Municipal Ta-Tung Hospital, Ministry of Health and Welfare, Ministry of Science and Technology, Taiwan.
Abstract (Originalsprache)
OBJECTIVES: The weekly rifapentine plus isoniazid for 3 months (3HP) improves completion rate of latent tuberculosis infection treatment, but flu-like symptoms are common. The novel 1HP regimen, involving daily rifapentine plus isoniazid for 28 days, has demonstrated low toxicity in HIV-infected populations. We aimed to investigate whether 1HP has a lower incidence rate of systemic drug reaction (SDR) compared with 3HP during treatment in non-HIV populations. METHODS: This randomized, multicentre trial compared the completion rate and risks of SDRs of 1HP and 3HP in aged ≥13 years non-HIV subjects with latent tuberculosis infection between September 2019 and September 2023 (ClinicalTrials.gov: NCT04094012). We also investigated associations between SDRs and plasma levels of drugs and their metabolites. RESULTS: A total of 251 and 239 individuals were randomly assigned to 1HP and 3HP groups, respectively, with completion rates of 82.9% (208/251) and 84.5% (202/239), respectively. Among them, 12.7% (32/251) and 10.9% (26/239) of 1HP and 3HP groups experienced SDRs, respectively (p 0.522), predominantly urticaria in 1HP group (59.4% [19/32]) and flu-like syndrome in 3HP group (80.8% [21/26]). Among participants experiencing SDRs, 43.8% (14/32) and 34.6% (9/26) in 1HP and 3HP groups, respectively, completed treatment (p 0.470). Cutaneous reactions were more common in 1HP than 3HP group (32.7% [82/251] vs. 13.0% [31/239], p < 0.001). In 1HP group, urticaria was associated with a higher plasma desacetyl-rifapentine level (ug/mL) at both 2 (median [interquartile range]: 36.06 [17.46-50.79] vs. 22.94 [14.67-31.65], p 0.018) and 6 hours (26.13 [15.80-53.06] vs. 29.83 [18.13-34.01], p 0.047) after dosing. DISCUSSION: In non-HIV population, the incidence rate of SDR under 1HP is not lower than 3HP. Notably, urticaria, rather than flu-like syndrome, was the predominant SDR associated 1HP. The findings of this study underscore the feasibility of 1HP regimen in non-HIV populations with a high-completion rate exceeding 80%.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiu…
- Department of Internal Medicine, National Taiwan University Hospital, Hsinchu Branch, Hsinchu, Taiwan; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; National Taiwan University, Co…
- Division of Pulmonary Medicine and Pulmonary Research Center, Wanfang Hospital, Taipei Medical University, Taipei, Taiwan.
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsi…
- Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; Center for Liquid Biopsy and Cohort Research, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
- Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; National Taiwan University, College of Medicine, Taipei, Taiwan. Electronic address: jywang@ntu.edu.tw.
Förderung
- Kaohsiung Municipal Ta-Tung Hospital
- Ministry of Health and Welfare
- Ministry of Science and Technology, Taiwan
- Ministry of Science and Technology
Zitieren
APA
Huang, H. L., Lee, M. R., Lee, C. H., Cheng, M. H., Lu, P. L., Sheu, C. C., Wang, J. Y., Chong, I. W., & Yang, J. M. (2024). One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection in non-HIV Population: a randomized controlled trial. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2024.06.024
Vancouver
Huang HL, Lee MR, Lee CH, Cheng MH, Lu PL, Sheu CC, et al. One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection in non-HIV Population: a randomized controlled trial. Clinical Microbiology and Infection. 2024. doi:10.1016/j.cmi.2024.06.024
BibTeX
@article{Huang2024,
author = {Huang, Hung-Ling and Lee, Meng-Rui and Lee, Chih-Hsin and Cheng, Meng-Hsuan and Lu, Po-Liang and Sheu, Chau-Chyun and Wang, Jann-Yuan and Chong, Inn-Wen and Yang, Jinn-Moon},
title = {One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection in non-HIV Population: a randomized controlled trial},
journal = {Clinical Microbiology and Infection},
year = {2024},
doi = {10.1016/j.cmi.2024.06.024}
}
EUVIMED